Tyree James L's Form 4 filing
ChemoCentryx, Inc. · filed Jun 13, 2022
- Accession no.
- 0001209191-22-036438
- Filed
- Jun 13, 2022
- Trade date
- Jun 9, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $99.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tyree James LCIK 0001324991 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 9, 2022 | Common Stock | SSaleDisposed | −3,804 | $25.65F2 | −$97,572.6 | 19,197 | Direct | |
| Jun 9, 2022 | Common Stock | SSaleDisposed | −59 | $26.22 | −$1,546.98 | 19,138 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $25.15 to $26.13 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.